NIOX Group Plc
CSSPF
Other OTC0.80
USD
- -
- -
ISIN
GB00BJVD3B28
Return %
Stock
S&P500
1Y
15.89
26.53
3Y
66.59
76.60
5Y
73.84
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jonathan Charles Emms
- Full Time Employees
- 91
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Hayakawa Building Oxford United Kingdom OX4 4GB
- IPO Date
- Feb 3, 2020
- Website
- investors.niox.com
- Similar Companies
- Business
- NIOX Group Plc is a United Kingdom-based medical device company that specializes in the design, development, and commercialization of products aimed at improving the diagnosis and management of asthma through monitoring airway inflammation. The company's core product portfolio centers around its market-leading NIOX® devices, which measure fractional exhaled nitric oxide (FeNO) to assess airway inflammation. The flagship product, NIOX VERO®, is a non-invasive, point-of-care system widely used by healthcare professionals globally for rapid standardized FeNO testing to assist in asthma diagnosis and management. NIOX also offers associated testing kits and digital health solutions to support clinical and research applications. The company operates primarily in the Asia Pacific region, the European Union, the United States, the United Kingdom, and several other markets worldwide. NIOX Group was founded in 2006 and is headquartered in Oxford, United Kingdom. It markets its products through a combination of direct sales and an extensive global distributor network covering over 50 countries, supported by strategic partnerships that provide product development, manufacturing, regulatory, and commercial distribution expertise. The company is actively expanding its geographic footprint with new distribution agreements in countries including the US, Italy, and Germany. Recent major developments include the ongoing development and expected launch in Q4 2025 of the next-generation NIOX PRO® device, which will feature improved ergonomics, a larger screen, and enhanced connectivity with iOS and Android platforms while maintaining compatibility with existing test kits. In 2024, NIOX forged a partnership with ZEPHYRx® to integrate NIOX FeNO measurements into the ZEPHYRx Respiratory Cloud Platform to advance respiratory clinical research. Additionally, the company is pursuing strategic growth through acquisitions and collaborations; notably, it announced plans to acquire Prosonix Limited, a specialty pharmaceutical company developing treatments for asthma and chronic obstructive pulmonary disease (COPD), for up to £100 million to expand its pipeline of near-term respiratory products and leverage existing commercial infrastructure. NIOX Group's strategic priorities include broadening market penetration in emerging regions such as Asia Pacific and Latin America, where it targets a combined market opportunity of approximately $1 billion, and strengthening partnerships to enhance product development and supply chain capabilities. The company maintains a focus on improving clinical outcomes in respiratory diseases through innovation in diagnostic and therapeutic technologies. Overall, NIOX Group Plc operates as a specialized medical device company that leverages its core FeNO measurement technology and expanding pharmaceutical pipeline to serve healthcare providers, clinical research organizations, and patients globally in the respiratory disease segment. Its recent product developments, strategic acquisitions, and partnerships reflect its ambition to be a comprehensive provider of respiratory diagnostics and therapies.